Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 1, p. s519, 2025. DOI: 10.25251/skin.9.supp.519. Disponível em: https://skin.dermsquared.com/skin/article/view/3158. Acesso em: 30 may. 2025.